Survival Outcomes and Impact of Targeted PAH Therapy in Portopulmonary Hypertension in the PVRI GoDeep Meta-Registry

Portopulmonary hypertension (PoPH), a type of pulmonary arterial hypertension (PAH) in patients with liver disease, is associated with high morbidity and mortality. The relationship between cardiopulmonary hemodynamics, PAH therapy, and survival in PoPH remains unclear. We performed a retrospective cohort study of PoPH patients from the international pulmonary hypertension (PH) meta-registry, PVRI GoDeep. PAH was defined by a mean pulmonary arterial pressure > 20 mmHg, pulmonary arterial wedge pressure

• Jose, A.
• Yogeswaran, A.
• Fuenderich, M.
• Kiely, D.
• Sweatt, A. J.
• Zamanian, R. T.
• Hassoun, P. M.
• Mouawad, A.
• Balasubramanian, A.
• Wilkins, M.
• Lawrie, A.
• Howard, L.
• Sahay, S.
• Olschewski, H.
• Kovacs, G.
• Saleh, K.
• Sabbour, H.
• Eichstaedt, C. A.
• Grünig, E.
• Giannakoulas, G.
• Arvanitaki, A.
• Sirenko, Y.
• Torbas, O.
• Cajigas, H.
• Frantz, R.
• Scelsi, L.
• Ghio, S.
• Majeed, R. W.
• Wilhelm, J.
• Ghofrani, H. A.
• Grimminger, F.
• Tello, K.
• Elwing, J.
• Seeger, W.